Cleared Traditional

K133522 - RIGHTEST DIABETES MANAGEMENT SOFTWARE AND ADAPTER (EXISTING CLEARED K113007),RIGHTEST NEW ADAPTERS-3,GE DIABETES MANAGEM

K133522 is an FDA 510(k) clearance for RIGHTEST DIABETES MANAGEMENT SOFTWARE A..., manufactured by Bionime Coporation. The device is a Class 2 Chemistry device with product code NBW cleared through the Traditional 510(k) pathway after a 153-day FDA review.

K133522 · Bionime Coporation · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2014
Decision
153d
Days
Class 2
Risk

K133522 is an FDA 510(k) clearance for the RIGHTEST DIABETES MANAGEMENT SOFTWARE AND ADAPTER (EXISTING CLEARED K113007),.... Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Bionime Coporation (Mission Viejo, US). The FDA issued a Cleared decision on April 17, 2014 after a review of 153 days - an extended review cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Bionime Coporation devices

FDA 510(k) Submission Details - K133522

510(k) Number K133522 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 15, 2013
Decision Date April 17, 2014
Days to Decision 153 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
65d slower than avg
Panel avg: 88d · This submission: 153d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NBW Device Classification - Class 2, Special Controls

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 420
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K133522.
IHEALTH ALIGN MINI GLUCO-MONITORING SYSTEM
K133790 · Andon Health Co, Ltd. · May 2014
ACCU-CHEK AVIVA PLUS SYSTEM
K133862 · Roche Diagnostics Corporation · Apr 2014
ELEMENTV BLOOD GLUCOSE MONITORING SYSTEM
K132406 · Infopia Co, Ltd. · Apr 2014
EM40 SELF-MONITORING BLOOD GLUCOSE SYSTEM
K133389 · Eps Bio Technology Corp. · Apr 2014
ELEMENT TM LITE BLOOD GLUCOSE MONITORING SYSTEM
K133045 · Infopia Co, Ltd. · Apr 2014
EMV3.1 PRO BLOOD GLUCOSE SYSTEM AND EMV3.1 SELF MONITORING BLOOD GLUCOSE SYSTEM
K133647 · Eps Bio Technology Corp. · Feb 2014